Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of ...
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP071 ...
MP0533 is a novel tetraspecific T cell engaging DARPin which simultaneously targets the three tumor-associated antigens (TAAs) CD33, CD123 and CD70, as well as CD3 on T cells. The mechanism of action ...
Proteins are the workhorses of cells and provide vital insights to cell health and disease function. Immunoassays and mass spectrometry are well established methods for studying proteins and have led ...
Trying to untangle a knot in a mess of strings can be frustrating and time-consuming. But not so for molecular ...
A new technique based on fluorescence resonance energy transfer (FRET)-based single-molecule protein fingerprinting can identify where specific amino acids and post-translational modifications are ...
Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results